Making a difference to the people we help treat by creating value and improving healthcare outcomes through connecting innovative manufacturers with Australasian customers.

The 2025-26 Merck Analyte Quarterly Update is Here!

Beyond Biomarkers! 

Expect reliable measurements, a simplified user experience, and knowledgeable scientific partners to help drive your biomarker projects. Abacus dx is committed to delivering the best possible immunoassays from Merck for your research needs.

Whether you are using Merck’s industry-leading MILLIPLEX® multiplex panels to broadly survey multiple analytes, performing femtogram/mL biomarker analysis using the FemtoQuest™ ultrasensitive immunoassay platform, or examining single proteins with our tried-and-true ELISAs and RIAs, you can confidently expect reliable measurements, a simplified user experience, and knowledgeable scientific partners to help drive your biomarker project from hypothesis to publication.

2025-26 Merck Analyte Quarterly Update

Download Here >


2025-26 Merck Analyte Quarterly Update

Download Here >

Request a Quote

Request Quote

Recent Posts

Roche – New KAPA NGS Reagents

Roche KAPA kits offer a range of high-performance products for molecular biology applications in next-generation sequencing (NGS). KAPA RNA EvoPrep Kit The KAPA RNA EvoPrep…

Read full article

2027 Abacus dx Emerging Investigators Grant

COMING SOON Grant in Research Funding Empowering the Next Generation of Scientific Leaders Stay tuned for the 2027 Abacus dx Emerging Investigators Grant. More information…

Read full article

Developing Diagnostic Kits for Ovarian Cancer

In Australia, ovarian cancer is the deadliest reproductive cancer. The average five‑year survival rate sits at around 49%, compared with about 92% for breast cancer,…

Read full article